384 related articles for article (PubMed ID: 24532475)
1. Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model.
Hantel C; Jung S; Mussack T; Reincke M; Beuschlein F
Endocr Relat Cancer; 2014 Jun; 21(3):383-94. PubMed ID: 24532475
[TBL] [Abstract][Full Text] [Related]
2. Preclinical progress and first translational steps for a liposomal chemotherapy protocol against adrenocortical carcinoma.
Jung S; Nagy Z; Fassnacht M; Zambetti G; Weiss M; Reincke M; Igaz P; Beuschlein F; Hantel C
Endocr Relat Cancer; 2016 Oct; 23(10):825-37. PubMed ID: 27550961
[TBL] [Abstract][Full Text] [Related]
3. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer.
Berruti A; Terzolo M; Pia A; Angeli A; Dogliotti L
Cancer; 1998 Nov; 83(10):2194-200. PubMed ID: 9827725
[TBL] [Abstract][Full Text] [Related]
4. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
Abraham J; Bakke S; Rutt A; Meadows B; Merino M; Alexander R; Schrump D; Bartlett D; Choyke P; Robey R; Hung E; Steinberg SM; Bates S; Fojo T
Cancer; 2002 May; 94(9):2333-43. PubMed ID: 12015757
[TBL] [Abstract][Full Text] [Related]
5. Mitotane associated with cisplatin, etoposide, and doxorubicin in advanced childhood adrenocortical carcinoma: mitotane monitoring and tumor regression.
Zancanella P; Pianovski MA; Oliveira BH; Ferman S; Piovezan GC; Lichtvan LL; Voss SZ; Stinghen ST; Callefe LG; Parise GA; Santana MH; Figueiredo BC
J Pediatr Hematol Oncol; 2006 Aug; 28(8):513-24. PubMed ID: 16912591
[TBL] [Abstract][Full Text] [Related]
6. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial.
Berruti A; Terzolo M; Sperone P; Pia A; Della Casa S; Gross DJ; Carnaghi C; Casali P; Porpiglia F; Mantero F; Reimondo G; Angeli A; Dogliotti L
Endocr Relat Cancer; 2005 Sep; 12(3):657-66. PubMed ID: 16172198
[TBL] [Abstract][Full Text] [Related]
7. Targeting heterogeneity of adrenocortical carcinoma: Evaluation and extension of preclinical tumor models to improve clinical translation.
Hantel C; Shapiro I; Poli G; Chiapponi C; Bidlingmaier M; Reincke M; Luconi M; Jung S; Beuschlein F
Oncotarget; 2016 Nov; 7(48):79292-79304. PubMed ID: 27764813
[TBL] [Abstract][Full Text] [Related]
8. Liposomal doxorubicin-based treatment in a preclinical model of adrenocortical carcinoma.
Hantel C; Lewrick F; Reincke M; Süss R; Beuschlein F
J Endocrinol; 2012 May; 213(2):155-61. PubMed ID: 22407999
[TBL] [Abstract][Full Text] [Related]
9. Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study.
Williamson SK; Lew D; Miller GJ; Balcerzak SP; Baker LH; Crawford ED
Cancer; 2000 Mar; 88(5):1159-65. PubMed ID: 10699907
[TBL] [Abstract][Full Text] [Related]
10. Adrenocortical carcinoma.
van Ditzhuijsen CI; van de Weijer R; Haak HR
Neth J Med; 2007 Feb; 65(2):55-60. PubMed ID: 17379929
[TBL] [Abstract][Full Text] [Related]
11. Lack of long-lasting effects of mitotane adjuvant therapy in a mouse xenograft model of adrenocortical carcinoma.
Doghman M; Lalli E
Mol Cell Endocrinol; 2013 Dec; 381(1-2):66-9. PubMed ID: 23906534
[TBL] [Abstract][Full Text] [Related]
12. Combination chemotherapy in advanced adrenocortical carcinoma.
Fassnacht M; Terzolo M; Allolio B; Baudin E; Haak H; Berruti A; Welin S; Schade-Brittinger C; Lacroix A; Jarzab B; Sorbye H; Torpy DJ; Stepan V; Schteingart DE; Arlt W; Kroiss M; Leboulleux S; Sperone P; Sundin A; Hermsen I; Hahner S; Willenberg HS; Tabarin A; Quinkler M; de la Fouchardière C; Schlumberger M; Mantero F; Weismann D; Beuschlein F; Gelderblom H; Wilmink H; Sender M; Edgerly M; Kenn W; Fojo T; Müller HH; Skogseid B;
N Engl J Med; 2012 Jun; 366(23):2189-97. PubMed ID: 22551107
[TBL] [Abstract][Full Text] [Related]
13. Clinical management and outcomes associated with etoposide, doxorubicin, and cisplatin plus mitotane treatment in metastatic adrenocortical carcinoma: a single institute experience.
Uchihara M; Tanioka M; Kojima Y; Nishikawa T; Sudo K; Shimoi T; Noguchi E; Maeshima AM; Yonemori K
Int J Clin Oncol; 2021 Dec; 26(12):2275-2281. PubMed ID: 34468885
[TBL] [Abstract][Full Text] [Related]
14. [Three Cases of Advanced or Recurrent Adrenocortical Carcinoma Patients Treated with Etoposide, Doxorubicin and Cisplatin plus Mitotane].
Sasaki S
Gan To Kagaku Ryoho; 2018 Jan; 45(1):67-70. PubMed ID: 29362311
[TBL] [Abstract][Full Text] [Related]
15. Next-generation therapies for adrenocortical carcinoma.
Altieri B; Ronchi CL; Kroiss M; Fassnacht M
Best Pract Res Clin Endocrinol Metab; 2020 May; 34(3):101434. PubMed ID: 32622829
[TBL] [Abstract][Full Text] [Related]
16. Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma.
Malandrino P; Al Ghuzlan A; Castaing M; Young J; Caillou B; Travagli JP; Elias D; de Baere T; Dromain C; Paci A; Chanson P; Schlumberger M; Leboulleux S; Baudin E
Endocr Relat Cancer; 2010 Sep; 17(3):797-807. PubMed ID: 20592067
[TBL] [Abstract][Full Text] [Related]
17. Conventional chemotherapy and emerging targeted therapy for advanced adrenocortical carcinoma.
Xu YZ; Zhu Y
Anticancer Agents Med Chem; 2013 Feb; 13(2):248-53. PubMed ID: 22934700
[TBL] [Abstract][Full Text] [Related]
18. The aurora kinase inhibitor AMG 900 increases apoptosis and induces chemosensitivity to anticancer drugs in the NCI-H295 adrenocortical carcinoma cell line.
Borges KS; Andrade AF; Silveira VS; Marco Antonio DS; Vasconcelos EJR; Antonini SRR; Tone LG; Scrideli CA
Anticancer Drugs; 2017 Jul; 28(6):634-644. PubMed ID: 28410270
[TBL] [Abstract][Full Text] [Related]
19. Topoisomerase 2α and thymidylate synthase expression in adrenocortical cancer.
Roca E; Berruti A; Sbiera S; Rapa I; Oneda E; Sperone P; Ronchi CL; Ferrari L; Grisanti S; Germano A; Zaggia B; Scagliotti GV; Fassnacht M; Volante M; Terzolo M; Papotti M
Endocr Relat Cancer; 2017 Jul; 24(7):319-327. PubMed ID: 28432084
[TBL] [Abstract][Full Text] [Related]
20. Update in adrenocortical carcinoma.
Fassnacht M; Kroiss M; Allolio B
J Clin Endocrinol Metab; 2013 Dec; 98(12):4551-64. PubMed ID: 24081734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
